(Q48386105)

English

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients

scientific article published on 15 September 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

multiple sclerosis

0 references

0 references

magnetic resonance imaging

0 references

8

7

object named as

Mar Tintoré

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

object named as

Carmen Tur

9

0 references

object named as

Maria A Rocca

11

0 references

Massimo Filippi

object named as

Massimo Filippi

10

0 references

13

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

Frederik Barkhof

15

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

12

object named as

Franz Fazekas

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

David H. Miller

3

object named as

David Miller

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

Mike P. Wattjes

1

object named as

Mike P Wattjes

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

4

object named as

Tarek A Yousry

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

Xavier Montalban

16

object named as

Xavier Montalban

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

MAGNIMS study group

17

object named as

MAGNIMS study group

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

2

object named as

Àlex Rovira

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

14

object named as

Chris Polman

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

author name string

Maria P Sormani

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

Maria P de Stefano

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

language of work or name

0 references

publication date

15 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

Nature Reviews Neurology

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

11

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

10

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

597-606

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

copyright license

Creative Commons Attribution 4.0 International

15 September 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation".

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Established and novel disease-modifying treatments in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

The clinico-radiological paradox in multiple sclerosis revisited

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Brainstem lesions in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Early MRI in optic neuritis: the risk for disability

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Spinal-cord MRI in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Novel therapeutic options for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Imaging outcomes for trials of remyelination in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Clinical relevance of brain volume measures in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Gray matter atrophy in multiple sclerosis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Brain atrophy and lesion load predict long term disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Gray matter damage predicts the accumulation of disability 13 years later in MS.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Revisiting brain atrophy and its relationship to disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Association between pathological and MRI findings in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetization transfer MR imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Diffusion tensor MR imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Proton magnetic resonance spectroscopy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Quantitative MR imaging of brain iron: a postmortem validation study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Future MRI tools in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

European Study on Intravenous Immunoglobulin in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Measures in the first year of therapy predict the response to interferon β in MS

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Predicting responders to therapies for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

A method for evaluating treatment switching criteria in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Clinical impact of early brain atrophy in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Defining and scoring response to IFN-β in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Scoring treatment response in patients with relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Improved detection of active multiple sclerosis lesions: 3D subtraction imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Automated identification of brain new lesions in multiple sclerosis using subtraction images

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

MRI pattern in asymptomatic natalizumab-associated PML.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Changes to anti-JCV antibody levels in a Swedish national MS cohort

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

PML in a patient with lymphocytopenia treated with dimethyl fumarate

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Tumefactive multiple sclerosis lesions under fingolimod treatment

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Tumefactive MS lesions under fingolimod: a case report and literature review

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Neuroprotection and repair in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Grey matter pathology in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Cortical pathology and cognitive impairment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Cortical lesion load associates with progression of disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

The grey matter correlates of impaired decision-making in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Accumulation of cortical lesions in MS: relation with cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Ultra-high-field MR imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Ultra-high field MRI: looking through the 'macroscope'

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Inflammation high-field magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.157

31 March 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardized magnetic resonance imaging acquisition and reporting in pediatric multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRNEUROL.2015.157

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/26369511

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48386105&oldid=2209407631"